Needle-Free mRNA Vaccine Booster Seeks India's Authorization

Following assessing the primary endpoints of the Phase II/III study, PharmaJet partner Gennova Biopharmaceuticals Limited has submitted data for its mRNA-based Omicron-specific Covid-19 booster shot for Emergency Use Authorization to the office of the Drug Controller General of India.

This is the first booster in India explicitly targeting the SARS-CoV-2 coronavirus Omicron variant.

GEMCOVAC-OM is a lyophilized vaccine, stable at 2-8 °C, which means it can be distributed through the existing refrigeration supply chain Pan-India and in low- and middle-income countries.

The vaccine, GEMCOVAC-OM, will be delivered exclusively with the PharmaJet Tropis Precision Delivery System.

"Our partnership with Gennova Pharma and their Omicron booster clinical program confirms the value of choosing our widely validated and rapidly scalable Precision Delivery Systems to improve the effectiveness of DNA and mRNA vaccines," said Chris Cappello, President, and CEO, PharmaJet, in a press release on April 3, 2023. 

"The Tropis System is already commercially available in India, and we are well-prepared to rapidly support demand for the GEMCOVAC-OM Omicron booster."

"In addition, we look forward to continuing our partnership with Gennova with additional novel vaccines."

For more information, visit Pharmajet's website.